



First Quarter 2017 Financial and Operational Results Slides to Accompany Investor Conference Call

May 3, 2017 NASDAQ:**AMRN**



MARIN

Forward-looking statements

This presentation contains forward-looking statements, such as those relating to the commercial potential of Vascepa[®], Amarin's product development, clinical and regulatory efforts and timelines, potential FDA approvals, intellectual property, cash flow, and other statements that are predictive in nature and that depend upon or refer to future events or conditions, including financial guidance and milestones. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC for a more complete description of risks of an investment in Amarin.

Presentation is for investors (not drug promotion)

This presentation is intended for communication with investors only.

Nothing in this presentation should be construed as promoting the use of Amarin's product or product candidates.

Q1 2017 Highlights



Q1 2017 U.S. Commercial Results

- Net product revenue grew to \$34.3 million, a 36% increase compared to Q1 2016
- Prescriptions increased by >50%; total patients on therapy increased to ~150,000
- Gross margin percentage increased to 76% vs. 73% for Q1 2016

International

- China regulatory authorities approved the Vascepa clinical trial
 - Partner in China aims to commence Vascepa clinical trial before the end of 2017


R&D

REDUCE-IT cardiovascular outcomes study >80% complete


Cash

- Ended March 2017 with \$96.1 million
- Improved cash flow such that net cash outflow from operations during Q1 2017 was < \$1.5 million excluding costs of R&D, financing, interest and royalties
 - Consistent with goal to be cash flow positive on same basis for full year

Vascepa Annual Net Product Revenue History and Guidance




Vascepa Quarterly Net Product Revenue History




- Normalized prescription growth driving overall net product revenue increase, however, quarterly variability reflects various factors including changes in inventory levels maintained by independent wholesalers
- Q1 of each year typically slow due to seasonal factors; year over year comparisons may be most representative

Vascepa Quarterly TRx History



Source: Symphony Health Solutions, PHAST



- Considerable growth opportunity remains
- Market share is higher in called upon targets than overall market share illustrated above

	<u>Today</u>	<u>Post REDUCE-IT</u> (assumes success)
Approved Promotion		
Based on surrogate biomarkers	Yes	Yes
Based on global outcomes study	No (none for any comp. Rx)	Yes
Population covered in label ¹		
TG <u>></u> 500 mg/dL	Yes	Yes - 3.8M patients
TG 200-499 mg/dL	No ²	Yes - 36M patients
TG 150-199 mg/dL	No	Yes - 30M patients 70M ⁴

Sales reps (U.S.)

¹Population data from NHANES [The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001 May. 285 (19): 2486-97]; populations of TGs <500 mg/dL being studied in statin treated patients with persistent high TGs

 139^{3}

²Current Vascepa label based on successful MARINE phase 3 study; under special agreement with FDA reached in 2016 gualified off-label promotion allowed including results of successful ANCHOR phase 3 study but label not expanded


³Current Amarin sales force targets approximately 20K physicians; additional outreach provided under co-promotion agreement with Kowa Pharmaceuticals America

⁴Population numbers include both patients on and not on statin therapy

MARIN

400 to 500

REDUCE-IT: Blinded Events Based Outcomes Assessment of CV Risk Reduction vs. Placebo



Primary endpoint - time to first occurrence of composite MACE

- MACE (major adverse cardiovascular events): CV death; non-fatal MI; non-fatal stroke; coronary revascularization; and hospitalization for unstable angina (caused by myocardial ischemia, determined by invasive or non-invasive testing)
- All events adjudicated by independent, blinded, Clinical Endpoint Committee
- >30 pre-specified secondary and tertiary endpoints

Designed under Special Protocol Assessment (SPA) agreement

Robustly powered study designed for 90% power to detect 15% relative risk reduction

- Assumes 1,612 primary endpoint events across a 4-5 year median patient follow-up period
- As with other long-term outcomes trials, actual study power may be higher or lower driven by typical factors such as the relative risk reduction observed between the treatment groups, the number of events observed at study completion and the aggregate time over which patients are studied

Same active ingredient (EPA) successful in JELIS, large Japanese outcomes study

- 19% reduction (p=0.011) in CV events in overall population (which didn't have high TGs)
- - REDUCE-IT design differences vs. JELIS include: higher EPA dose; lower LDL-C enrollment target; patients from 11 countries; and enriched, persistent high TG patient population; JELIS was open label, randomized with blinded endpoint analysis; unstable angina contributed more significantly to JELIS results than expected for REDUCE-IT

Multiple recent large genetic studies suggest TG and LDL-C levels are similar predictors of CHD

Do et al.: genes regulating TG and LDL-C levels correlated strongly with coronary heart disease (0.40 and 0.39, respectively; p<0.0001) vs. HDL-C having weak correlation (0.04; p=0.32)

Lower TG levels correlated with lower CHD risk when LDL-C is well controlled

PROVE-IT (Lipitor/Pravachol): Analysis of all patients well controlled for LDL (<70 mg/dL) in which patients with TG
<200 mg/dL were associated with 40% lower risk of recurrent CHD events vs TG ≥200 mg/dL

Subsets of patients in clinical outcomes studies evaluating therapies that lower TG levels have shown benefit in subset populations of patients with baseline elevated TG, despite failed trials


- ACCORD (Fenofibrate): Subgroup TG ≥204 mg/dL and HDL-C ≤34 mg/dL; MACE relative risk reduction 31%
- AIM-HIGH (Niacin ER): Subgroup TG ≥200 mg/dL and HDL-C <32 mg/dL; MACE relative risk reduction 36%

Supportive evidence of EPA's cardio-protective mechanisms beyond TG lowering

- CHERRY study: EPA + high dose statin ----> 2x plaque regression vs high dose statin alone
- Nosaka et al.: early EPA + statin post PCI —> 11% reduction in CV events vs statin alone; CV death reduced 3.4%
- Mechanistic effects of EPA have broad favorable effect on:
 - endothelial function
 - oxidative stress
 - foam cell formation
 - inflammation/cytokines

- plaque formation/progression
- platelet aggregation
- thrombus formation
- plaque rupture

REDUCE-IT: Recap of Positioning



Http://www.amarincorp.com/products.html. Updated March 7, 2016. Accessed April 4, 2016. 3. Sarwar N et al. Circulation. 2007;115(4):450-458; 4. Miller M et al. J Am Coll Cardiol. 2008;51(7):724-730; 5. Borow KM et al. Atherosclerosis. 2015;242(1)



Cash ¹	\$96.1	
Debt Obligations ²		
ROYALTY-BEARING DEBT ³	\$121.7	
EXCHANGEABLE SENIOR NOTES ⁴	\$30.0	
Common Stock and Equivalent Shares		
COMMON/PREFERRED SHARES ⁵	303.5	Preferred shares mirror common but non-voting
OPTIONS AND RESTRICTED STOCK	33.3	
TOTAL IF ALL EXERCISED	336.8	
Tax Jurisdiction (primary)	Ireland	Loss carryforwards of >\$570

¹ Includes net proceeds of approximately \$13.7M after debt restructuring in January 2017

² Represents face value of debt balance remaining to be paid in cash; a lower carrying value is reported for accounting purposes in accordance with U.S. GAAP

³ The total remaining cash payments due on this debt are a fixed amount and include the contractual interest, which is paid quarterly at 10% of Vascepa revenues subject to quarterly maximum amounts

- ⁴ During January 2017, ~\$15M of the 2012 Notes were put to the Company and the Company issued \$30M of 3.5% Exchangeable Senior Notes due 2047 resulting in a net increase of \$15M of Exchangeable Senior Notes
- ⁵ Includes 32.8 million common share equivalents issuable upon conversion of preferred shares

Consolidated Balance Sheet



	March 31, 2017		December 31, 2016	
	(in thousands)			
ASSETS				
Current Assets:				
Cash and cash equivalents	\$	96,076	\$	98,251
Restricted cash		600		600
Accounts receivable, net		29,450		19,985
Inventory		23,879		20,507
Prepaid and other current assets		4,785		6,983
Total current assets		154,790	-	146,326
Property, plant and equipment, net		69		78
Deferred tax assets		11,082		11,082
Other long-term assets		652		741
Intangible asset, net		8,610		8,772
TOTAL ASSETS	\$	175,203	\$	166,999
LIABILITIES AND STOCKHOLDERS' DEFICIT				
Current Liabilities:				
Accounts payable	\$	15,117	\$	6,062
Accrued expenses and other current liabilities	Ψ	44,434	Ψ	37,720
Current portion of exchangeable senior notes, net of discount		192		15,351
Current portion of long-term debt from royalty-bearing instrument		17,004		15,944
Deferred revenue, current		1,197		1,172
Total current liabilities		77,944		76,249
		· · · · ·		·
Long-Term Liabilities:				
Exchangeable senior notes, net of discount		28,831		
Long-term debt from royalty-bearing instrument		82,405		85,155
Deferred revenue, long-term		13,625		13,943
Other long-term liabilities		1,167		710
Total liabilities		203,972		176,057
Stockholders' Deficit:				
Preferred stock		24,364		24,364
Common stock		208,465		207,166
Additional paid-in capital		967,073		964,914
Treasury stock		(3,726)		(1,498)
Accumulated deficit		(1,224,945)		(1,204,004)
Total stockholders' deficit		(28,769)		(9,058)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$	175,203	\$	166,999

Consolidated Statements of Operations



	Three Months Ended March 31, (in thous ands, except per share amounts)			
	2017		2016	
Product revenue, net	\$	34,344	\$	25,307
Licensing revenue		293		236
Total revenue, net		34,637		25,543
Less: Cost of goods sold		8,198		6,896
Gross margin		26,439		18,647
Operating expenses:				
Selling, general and administrative (1)		34,171		28,020
Research and development (1)		10,823		13,730
Total operating expenses		44,994		41,750
Operating loss		(18,555)		(23,103)
Loss on change in fair value of derivative liabilities (2)		_		(1,250)
Interest expense, net		(2,381)		(5,586)
Other expense, net		(5)		(121)
Loss from operations before taxes		(20,941)		(30,060)
Benefit from income taxes	_	—		289
Net loss	\$	(20,941)	\$	(29,771)
Loss per share:				
Basic	\$	(0.08)	\$	(0.16)
Diluted	\$	(0.08)	\$	(0.16)
Weighted average shares:				
Basic		270,163		184,052
Diluted		270,163		184,052

- (1) Excluding non-cash stock-based compensation, selling, general and administrative expenses were \$31,343 and \$25,136 for the three months ended March 31, 2017 and 2016, respectively, and research and development expenses were \$10,300 and \$13,017, respectively, for the same periods. Excluding non-cash stock-based compensation as well as co-promotion fees paid to our U.S. copromotion partner, selling, general and administrative expenses were \$26,111 and \$21,638 for the three months ended March 31, 2017 and 2016, respectively.
- (2) Non-cash gains and losses result from changes in the fair value of a warrant derivative liability, long-term debt derivative liabilities, and a preferred stock purchase option derivative liability.